Botanix Pharmaceuticals Not Expected to be Impacted by Trump's Executive Orders, Euroz Hartleys Says

MT Newswires Live
05/13

Botanix Pharmaceuticals (ASX:BOT) is currently expected to have little to no impact from the executive order by Trump to lower drug prices in the US, Euroz Hartley said in a Tuesday note.

The research firm noted that the company's drug Sofdra is only approved and sold in the US, lacking an international price for reference.

Provisions in the order related to antitrust enforcement, pharmaceutical exports, or unsafe drug approvals are not relevant to the company or Sofdra, the note added.

Euroz Hartleys maintained Botanix Pharmaceuticals' buy rating with a price target of AU$0.80.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10